No Data
No Data
Entheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news r
Cybin to Buy Clinical Trial From Entheon Biomedical to Advance Development of CYB004
09:58 AM EDT, 06/07/2022 (MT Newswires) -- Cybin (CYBN) said Tuesday it has agreed to buy a phase 1 study from Entheon Biomedical for $1 million Canadian dollars ($794,450) to boost the clinical devel
BRIEF-Cybin Acquires Dmt Clinical Study From Entheon Biomedical
June 7 (Reuters) - Cybin Inc CYBN.NLB :* CYBIN ACQUIRES DMT CLINICAL STUDY FROM ENTHEON BIOMEDICAL* CYBIN INC- PURCHASE PRICE OF ACQUISITION IS $1,000,000 (CAD)Source text for Eikon: ID:nBw20D4Bma
Cybin to acquire DMT clinical study from Entheon Biomedical
Cybin (NYSE:CYBN) added ~8% in the pre-market Tuesday after the psychedelics-focused biopharma announced that its subsidiary Cybin IRL Limited agreed to acquire a Phase 1 N,N-dimethyltryptamine ("DMT"
Cybin Acquires DMT Clinical Study From Entheon Biomedical For C$1M
Cybin Acquires DMT Clinical Study From Entheon Biomedical For C$1M
Cybin to Buy DMT Clinical Study From Entheon Biomedical >CYBN
Cybin to Buy DMT Clinical Study From Entheon Biomedical >CYBN